XENE Xenon Pharmaceuticals | 9/18/2026 | Lower Price Target | $41.17 | $70.00 | Outperform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 9/11/2026 | Reiterated Rating | $38.60 | $66.00 | Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 9/10/2026 | Downgrade | $8.81 | $11.00 | Sector Perform | $0.00 00.00% ROI | |
EVMN Evommune | 9/9/2026 | Lower Price Target | $11.25 | $21.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 9/8/2026 | Reiterated Rating | $156.07 | $198.00 | Outperform | $0.00 00.00% ROI | |
ATTO Attovia Therapeutics | 8/31/2026 | Initiated Coverage | $20.70 | $45.00 | Outperform | $0.00 00.00% ROI | |
ATTO Attovia Therapeutics | 8/30/2026 | Upgrade | $21.40 | | Moderate Buy | $0.00 00.00% ROI | |
BIIB Biogen | 8/25/2026 | Boost Price Target | $218.12 | $260.00 | Outperform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 8/13/2026 | Boost Price Target | $44.46 | $66.00 | Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 8/13/2026 | Boost Price Target | $34.56 | $52.00 | Outperform | $0.00 00.00% ROI | |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
LKFT Lakefront Biotherapeutics American Depositary Shares | 8/11/2026 | Lower Price Target | $27.96 | $26.00 | Sector Perform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 8/10/2026 | Boost Price Target | $25.57 | $36.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 8/7/2026 | Lower Price Target | $63.64 | $81.00 | Outperform | $0.00 00.00% ROI | |
EVMN Evommune | 8/7/2026 | Lower Price Target | $14.20 | $29.00 | Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 8/6/2026 | Lower Price Target | $9.42 | $13.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 8/5/2026 | Boost Price Target | $28.32 | $37.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 8/5/2026 | Boost Price Target | $130.70 | $123.00 | Sector Perform | $0.00 00.00% ROI | |
CTNM Contineum Therapeutics | 7/31/2026 | Boost Price Target | $15.27 | $23.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 7/31/2026 | Boost Price Target | $763.17 | $737.00 | Sector Perform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 7/31/2026 | Boost Price Target | $166.77 | $198.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 7/30/2026 | Lower Price Target | $205.31 | $240.00 | Outperform | $0.00 00.00% ROI | |
INCY Incyte | 7/29/2026 | Boost Price Target | $127.16 | $109.00 | Sector Perform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 7/13/2026 | Downgrade | $119.35 | $115.00 | Sector Perform | $0.00 00.00% ROI | |
NMRA Neumora Therapeutics | 7/13/2026 | Lower Price Target | $1.62 | $5.00 | Outperform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 7/10/2026 | Boost Price Target | $23.97 | $33.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 7/7/2026 | Boost Price Target | $529.59 | $570.00 | Outperform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 7/7/2026 | Boost Price Target | $85.44 | $85.00 | Sector Perform | $0.00 00.00% ROI | |
INCY Incyte | 7/7/2026 | Boost Price Target | $115.62 | $99.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 7/7/2026 | Boost Price Target | $208.46 | $242.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 7/7/2026 | Boost Price Target | $25.77 | $36.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 7/7/2026 | Lower Price Target | $668.88 | $696.00 | Sector Perform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 7/7/2026 | Boost Price Target | $178.11 | $195.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 7/7/2026 | Lower Price Target | $134.71 | $120.00 | Sector Perform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 7/7/2026 | Boost Price Target | $10.19 | $14.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 6/8/2026 | Reiterated Rating | $129.17 | | Sector Perform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 6/8/2026 | Boost Price Target | $86.92 | $97.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 6/1/2026 | Reiterated Rating | $134.43 | $122.00 | Overweight | $0.00 00.00% ROI | |
GILD Gilead Sciences | 6/1/2026 | Upgrade | $131.10 | | Moderate Buy | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 5/29/2026 | Boost Price Target | $157.47 | $183.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 5/27/2026 | Boost Price Target | $193.08 | $227.00 | Outperform | $0.00 00.00% ROI | |
The end may be near for these iconic stocks (Ad) Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
REGN Regeneron Pharmaceuticals | 5/18/2026 | Lower Price Target | $623.32 | $707.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 5/8/2026 | Lower Price Target | $130.55 | $122.00 | Sector Perform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 5/8/2026 | Boost Price Target | $79.08 | $82.00 | Sector Perform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 5/8/2026 | Boost Price Target | $55.89 | $82.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 5/6/2026 | Boost Price Target | $144.90 | $180.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 5/5/2026 | Boost Price Target | $429.85 | $543.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 4/30/2026 | Boost Price Target | $191.32 | $222.00 | Outperform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 4/30/2026 | Lower Price Target | $707.09 | $762.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 4/29/2026 | Boost Price Target | $191.58 | $222.00 | Outperform | $0.00 00.00% ROI | |
DMRA Damora Therapeutics, Inc. Common Stock | 4/24/2026 | Initiated Coverage | $25.42 | $40.00 | Outperform | $0.00 00.00% ROI | |
DMRA Damora Therapeutics, Inc. Common Stock | 4/23/2026 | Upgrade | $24.75 | | Moderate Buy | $0.00 00.00% ROI | |
EVMN Evommune | 4/10/2026 | Reiterated Rating | $27.56 | $48.00 | Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 4/6/2026 | Lower Price Target | $28.56 | $51.00 | Outperform | $0.00 00.00% ROI | |
PHVS Pharvaris | 3/9/2026 | Initiated Coverage | $26.63 | $52.00 | Outperform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 3/2/2026 | Lower Price Target | $70.92 | $82.00 | Sector Perform | $0.00 00.00% ROI | |
AARD Aardvark Therapeutics | 3/2/2026 | Downgrade | $12.49 | $6.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 3/2/2026 | Boost Price Target | $784.09 | $765.00 | Sector Perform | $0.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 3/2/2026 | Boost Price Target | $17.69 | $13.00 | Sector Perform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 2/26/2026 | Reiterated Rating | $91.56 | $108.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 2/26/2026 | Lower Price Target | $24.82 | $30.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 2/24/2026 | Boost Price Target | $34.36 | $33.00 | Sector Perform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 2/20/2026 | Lower Price Target | $69.90 | $82.00 | Sector Perform | $0.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 2/20/2026 | Boost Price Target | $17.86 | $12.00 | Sector Perform | $0.00 00.00% ROI | |
PRTA Prothena | 2/20/2026 | Boost Price Target | $8.83 | $12.00 | Sector Perform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 2/13/2026 | Lower Price Target | $496.69 | $541.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 2/12/2026 | Lower Price Target | $126.01 | $177.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 2/11/2026 | Boost Price Target | $156.39 | $118.00 | Sector Perform | $0.00 00.00% ROI | |
INCY Incyte | 2/11/2026 | Lower Price Target | $98.59 | $92.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 2/9/2026 | Boost Price Target | $201.18 | $233.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 2/3/2026 | Lower Price Target | $26.13 | $31.00 | Outperform | $0.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 1/30/2026 | Lower Price Target | $6.44 | $13.00 | Outperform | $0.00 00.00% ROI | |
NRIX Nurix Therapeutics | 1/29/2026 | Boost Price Target | $17.60 | $30.00 | Outperform | $0.00 00.00% ROI | |
GHRS GH Research | 1/23/2026 | Boost Price Target | $16.46 | $40.00 | Outperform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 1/23/2026 | Boost Price Target | $17.29 | $36.00 | Outperform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 1/22/2026 | Downgrade | $81.91 | $83.00 | Sector Perform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 1/22/2026 | Upgrade | $461.14 | $546.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 1/20/2026 | Boost Price Target | $124.91 | $103.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 1/13/2026 | Reiterated Rating | $178.30 | | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 1/8/2026 | Lower Price Target | $121.35 | $100.00 | Sector Perform | $0.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 1/8/2026 | Boost Price Target | $21.31 | $18.00 | Sector Perform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 1/6/2026 | Reiterated Rating | $78.59 | | Outperform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 12/16/2025 | Boost Price Target | $85.68 | $103.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 12/8/2025 | Boost Price Target | $159.46 | $180.00 | Outperform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 12/1/2025 | Downgrade | $85.99 | $91.00 | Sector Perform | $0.00 00.00% ROI | |
NMRA Neumora Therapeutics | 12/1/2025 | Upgrade | $2.26 | $7.00 | Outperform | $0.00 00.00% ROI | |
SION Sionna Therapeutics | 12/1/2025 | Reiterated Rating | $43.57 | $24.00 | Underperform | $0.00 00.00% ROI | |
CTNM Contineum Therapeutics | 11/21/2025 | Lower Price Target | $11.08 | $22.00 | Outperform | $0.00 00.00% ROI | |
CDTX Cidara Therapeutics | 11/17/2025 | Downgrade | $217.78 | | Sector Perform | $0.00 00.00% ROI | |
AARD Aardvark Therapeutics | 11/14/2025 | Lower Price Target | $10.86 | $18.00 | Outperform | $0.00 00.00% ROI | |
CRBP Corbus Pharmaceuticals | 11/13/2025 | Lower Price Target | $11.09 | $53.00 | Outperform | $0.00 00.00% ROI | |
Ready to give options a try? Your first trade (Ticker included) -INSIDE (Ad) Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow. Send me my free guide |
PRTA Prothena | 11/7/2025 | Boost Price Target | $10.15 | $11.00 | Sector Perform | $0.00 00.00% ROI | |
DFTX Definium Therapeutics | 11/7/2025 | Lower Price Target | $11.26 | $20.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 11/7/2025 | Boost Price Target | $31.38 | $32.00 | Sector Perform | $0.00 00.00% ROI | |
CDTX Cidara Therapeutics | 11/7/2025 | Boost Price Target | $99.95 | $145.00 | Outperform | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 11/6/2025 | Lower Price Target | $21.35 | $32.00 | Outperform | $0.00 00.00% ROI | |
PTCT PTC Therapeutics | 11/5/2025 | Boost Price Target | $72.90 | $82.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 11/4/2025 | Boost Price Target | $39.54 | $58.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 11/4/2025 | Lower Price Target | $430.41 | $415.00 | Sector Perform | $0.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 11/4/2025 | Lower Price Target | $5.66 | $19.00 | Outperform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 11/3/2025 | Boost Price Target | $57.13 | $70.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 10/31/2025 | Lower Price Target | $149.61 | $210.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 10/31/2025 | Boost Price Target | $120.73 | $105.00 | Sector Perform | $0.00 00.00% ROI | |
INCY Incyte | 10/29/2025 | Boost Price Target | $89.19 | $84.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 10/29/2025 | Boost Price Target | $654.96 | $708.00 | Sector Perform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 10/29/2025 | Boost Price Target | $139.82 | $160.00 | Outperform | $0.00 00.00% ROI | |
LKFT Lakefront Biotherapeutics American Depositary Shares | 10/22/2025 | Boost Price Target | $32.33 | $28.00 | Sector Perform | $0.00 00.00% ROI | |
BIIB Biogen | 10/8/2025 | Lower Price Target | $152.21 | $217.00 | Outperform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 10/8/2025 | Boost Price Target | $116.78 | $100.00 | Sector Perform | $0.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 10/8/2025 | Boost Price Target | $24.02 | $16.00 | Sector Perform | $0.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 9/29/2025 | Reiterated Rating | $6.86 | $10.00 | Sector Perform | $0.00 00.00% ROI | |
APGE Apogee Therapeutics | 9/25/2025 | Initiated Coverage | $38.42 | $60.00 | Outperform | $0.00 00.00% ROI | |
CDTX Cidara Therapeutics | 9/24/2025 | Set Price Target | $88.16 | $137.00 | Outperform | $0.00 00.00% ROI | |
INCY Incyte | 9/24/2025 | Boost Price Target | $84.54 | $81.00 | Sector Perform | $0.00 00.00% ROI | |
KYMR Kymera Therapeutics | 9/16/2025 | Initiated Coverage | $47.28 | $70.00 | Outperform | $000.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 9/5/2025 | Boost Price Target | $143.76 | $149.00 | Outperform | $000.00 00.00% ROI | |
SION Sionna Therapeutics | 9/3/2025 | Initiated Coverage | $25.39 | $22.00 | Sector Perform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 9/2/2025 | Reiterated Rating | $39.12 | $55.00 | Outperform | $00.00 00.00% ROI | |
AARD Aardvark Therapeutics | 8/14/2025 | Lower Price Target | $11.44 | $19.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 8/12/2025 | Lower Price Target | $36.96 | $55.00 | Outperform | $00.00 00.00% ROI | |
PTCT PTC Therapeutics | 8/8/2025 | Reiterated Rating | $46.87 | $63.00 | Outperform | $00.00 00.00% ROI | |
ETNB 89BIO | 8/8/2025 | Lower Price Target | $8.92 | $11.00 | Sector Perform | $0.00 00.00% ROI | |
GILD Gilead Sciences | 8/8/2025 | Boost Price Target | $119.21 | $98.00 | Sector Perform | $000.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 8/7/2025 | Boost Price Target | $23.84 | $40.00 | Outperform | $00.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 8/5/2025 | Lower Price Target | $389.93 | $405.00 | Sector Perform | $000.00 00.00% ROI | |
PRTA Prothena | 8/5/2025 | Lower Price Target | $7.28 | $10.00 | Sector Perform | $0.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 8/4/2025 | Boost Price Target | $569.71 | $695.00 | Sector Perform | $000.00 00.00% ROI | |
BIIB Biogen | 8/1/2025 | Boost Price Target | $126.28 | $219.00 | Outperform | $000.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 7/31/2025 | Lower Price Target | $129.41 | $144.00 | Outperform | $000.00 00.00% ROI | |
INCY Incyte | 7/30/2025 | Boost Price Target | $77.88 | $72.00 | Sector Perform | $000.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 7/17/2025 | Lower Price Target | $21.46 | $23.00 | Sector Perform | $00.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 6/30/2025 | Reiterated Rating | $9.23 | $13.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 6/25/2025 | Set Price Target | $126.16 | $213.00 | Outperform | $000.00 00.00% ROI | |
CDTX Cidara Therapeutics | 6/24/2025 | Upgrade | $49.86 | $75.00 | Moderate Buy | $0.00 00.00% ROI | |
ACAD ACADIA Pharmaceuticals | 6/23/2025 | Boost Price Target | $22.12 | $38.00 | Outperform | $00.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 6/17/2025 | Set Price Target | $448.47 | $420.00 | Sector Perform | $000.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 5/27/2025 | Reiterated Rating | $599.20 | $662.00 | Sector Perform | $000.00 00.00% ROI | |
CTNM Contineum Therapeutics | 5/15/2025 | Reiterated Rating | $3.72 | $31.00 | Outperform | $00.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 5/13/2025 | Lower Price Target | $5.40 | $33.00 | Outperform | $0.00 00.00% ROI | |
XENE Xenon Pharmaceuticals | 5/13/2025 | Lower Price Target | $29.93 | $55.00 | Outperform | $00.00 00.00% ROI | |
CRBP Corbus Pharmaceuticals | 5/7/2025 | Lower Price Target | $6.34 | $58.00 | Outperform | $00.00 00.00% ROI | |
Here’s the stock symbol I’ve promised (Ad) Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better.
This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. Get the stock name and ticker symbol free of charge today |
VRTX Vertex Pharmaceuticals | 5/6/2025 | Boost Price Target | $434.64 | $423.00 | Sector Perform | $000.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 5/6/2025 | Reiterated Rating | $10.40 | $13.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 5/2/2025 | Lower Price Target | $122.38 | $205.00 | Outperform | $000.00 00.00% ROI | |
INCY Incyte | 4/30/2025 | Boost Price Target | $61.11 | $67.00 | Sector Perform | $00.00 00.00% ROI | |
REGN Regeneron Pharmaceuticals | 4/30/2025 | Lower Price Target | $586.51 | $943.00 | Outperform | $000.00 00.00% ROI | |
LEGN Legend Biotech | 4/22/2025 | Reiterated Rating | $33.48 | $84.00 | Outperform | $00.00 00.00% ROI | |
BIIB Biogen | 4/22/2025 | Boost Price Target | $117.63 | $225.00 | Outperform | $000.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 4/14/2025 | Upgrade | $90.87 | $137.00 | Outperform | $000.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 4/11/2025 | Reiterated Rating | $6.55 | $11.00 | Outperform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 4/1/2025 | Boost Price Target | $487.06 | $420.00 | Sector Perform | $000.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 3/31/2025 | Downgrade | $70.41 | $87.00 | Sector Perform | $00.00 00.00% ROI | |
MLTX MoonLake Immunotherapeutics | 3/18/2025 | Initiated Coverage | $38.67 | $67.00 | Outperform | $00.00 00.00% ROI | |
AARD Aardvark Therapeutics | 3/10/2025 | Initiated Coverage | $10.13 | $21.00 | Outperform | $0.00 00.00% ROI | |
GHRS GH Research | 3/7/2025 | Initiated Coverage | $10.55 | $31.00 | Outperform | $00.00 00.00% ROI | |
SRPT Sarepta Therapeutics | 2/27/2025 | Lower Price Target | $107.24 | $161.00 | Outperform | $00.00 00.00% ROI | |
BCRX BioCryst Pharmaceuticals | 2/25/2025 | Reiterated Rating | $8.11 | $11.00 | Outperform | $0.00 00.00% ROI | |
PRTA Prothena | 2/21/2025 | Lower Price Target | $15.61 | $20.00 | Sector Perform | $0.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 2/20/2025 | Boost Price Target | $475.68 | $408.00 | Sector Perform | $000.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 2/20/2025 | Reiterated Rating | $9.41 | $45.00 | Outperform | $0.00 00.00% ROI | |
BIIB Biogen | 2/13/2025 | Lower Price Target | $135.56 | $225.00 | Outperform | $000.00 00.00% ROI | |
GILD Gilead Sciences | 2/12/2025 | Boost Price Target | $103.52 | $90.00 | Sector Perform | $000.00 00.00% ROI | |
INCY Incyte | 2/11/2025 | Lower Price Target | $68.30 | $68.00 | Sector Perform | $000.00 00.00% ROI | |
VRTX Vertex Pharmaceuticals | 2/11/2025 | Boost Price Target | $459.15 | $407.00 | Sector Perform | $000.00 00.00% ROI | |
PLRX Pliant Therapeutics | 2/10/2025 | Downgrade | $7.79 | $4.00 | Sector Perform | $0.00 00.00% ROI | |
KPTI Karyopharm Therapeutics | 2/10/2025 | Reiterated Rating | $9.77 | $45.00 | Outperform | $0.00 00.00% ROI | |
NBIX Neurocrine Biosciences | 2/7/2025 | Lower Price Target | $122.00 | $148.00 | Sector Perform | $000.00 00.00% ROI | |
GILD Gilead Sciences | 2/3/2025 | Reiterated Rating | $99.12 | $84.00 | Sector Perform | $000.00 00.00% ROI | |
AXSM Axsome Therapeutics | 1/29/2025 | Reiterated Rating | $104.53 | $139.00 | Outperform | $000.00 00.00% ROI | |